Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $1.75

Benzinga Newsdesk www.benzinga.com Negative 82.1%

Neg 82.1% Neu 0% Pos 0%

Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.75 to $1.75.